|
Age (years)
|
43.1 (±13.6)
|
43.0 (±12.9)
|
|
Women
|
1208 (78.3)
|
773 (78.8)
|
|
Education, A level or similar
|
965 (62.5)
|
542 (55.2)
|
|
Utilization of complementary medicine 12 months prior to baseline
|
955 (61.9)
|
119 (12.1)
|
|
Per-protocol initial anamnesis in HOM group
|
496 (32.1)
|
N/A
|
|
State of residence (n (%))
|
|
Abroad
|
2 (0.1)
|
0 (0)
|
|
Baden-Wuerttemberg
|
185 (12)
|
105 (10.7)
|
|
Bavaria
|
206 (13.4)
|
109 (11.1)
|
|
Berlin
|
188 (12.2)
|
59 (6.0)
|
|
Brandenburg
|
40 (2.6)
|
33 (3.4)
|
|
Bremen
|
14 (0.9)
|
10 (1.0)
|
|
Hamburg
|
103 (6.7)
|
56 (5.7)
|
|
Hesse
|
118 (7.6)
|
106 (10.8)
|
|
Mecklenburg-Western Pomerania
|
24 (1.6)
|
14 (1.4)
|
|
Lower Saxony
|
123 (8.0)
|
102 (10.4)
|
|
North-Rhine Westphalia
|
300 (19.4)
|
224 (22.8)
|
|
Rhineland-Palatinate
|
87 (5.6)
|
49 (5.0)
|
|
Saarland
|
7 (0.5)
|
7 (0.7)
|
|
Saxony
|
22 (1.4)
|
32 (3.3)
|
|
Saxony-Anhalt
|
18 (1.2)
|
13 (1.3)
|
|
Schleswig-Holstein
|
90 (5.8)
|
49 (5.0)
|
|
Thuringia
|
16 (1.0)
|
13 (1.3)
|
|
Diagnosis and specific measures
|
|
Migraine/headache (G43.9/ R51)
|
422 (27.3)
|
266 (27.1)
|
|
Days with headache (last 4 weeks)
|
7.2 (±6.1)
|
6.2 (±5.6)
|
|
Utility valuea
|
0.683 (±0.118)
|
0.711 (±0.125)
|
|
Total costs previous 12 months in € (insurer perspective)
|
1080.82 (±1064.27)
|
1138.07 (±938.70)
|
|
Total costs previous 12 months in € (societal perspective)
|
4399.99 (±8472.08)
|
4476.86 (±7713.43)
|
|
Allergic rhinitis (J30.1)
|
317 (20.5)
|
188 (19.2)
|
|
RQLQ(S) score
|
2.5 (±1.3)
|
1.8 (±1.3)
|
|
AdolRQLQ score
|
2.0 (±1.0)
|
2.1 (±1.1)
|
|
Utility valuea
|
0.727 (±0.124)
|
0.788 (±0.118)
|
|
Total costs previous 12 months in € (insurer perspective)
|
912.31 (±872.55)
|
973.18 (±726.53)
|
|
Total costs previous 12 months in € (societal perspective)
|
2716.87 (±5866.87)
|
2867.22 (±5675.07)
|
|
Asthma (J45.9)
|
123 (8.0)
|
81 (8.3)
|
|
AQLQ(S) score
|
5.1 (±0.9)
|
5.5 (±1.1)
|
|
PAQLQ score
|
4.3 (±1.1)
|
5.8 (±0.8)
|
|
Utility valuea
|
0.750 (±0.123)
|
0.788 (±0.126)
|
|
Total costs previous 12 months in € (insurer perspective)
|
1233.89 (±1226.28)
|
1182.97 (±1071.87)
|
|
Total costs previous 12 months in € (societal perspective)
|
3913.54 (±7459.30)
|
3191.32 (±5544.62)
|
|
Atopic dermatitis (L20)
|
229 (14.8)
|
105 (10.7)
|
|
DLQI score
|
8.9 (±6.1)
|
6.1 (±5.4)
|
|
CDLQI score
|
6.6 (±4.3)
|
2.8 (±2.9)
|
|
Utility valuea
|
0.743 (±0.128)
|
0.788 (±0.119)
|
|
Total costs previous 12 months in € (insurer perspective)
|
929.83 (±874.23)
|
834.08 (±805.37)
|
|
Total costs previous 12 months in € (societal perspective)
|
3150.44 (±7876.47)
|
2644.33 (±3251.03)
|
|
Depression (F32.9)
|
452 (29.3)
|
341 (34.8)
|
|
BDI-II Score
|
23.3 (±10.0)
|
20.3 (±11.3)
|
|
Utility valuea
|
0.621 (±0.103)
|
0.666 (±0.123)
|
|
Total costs previous 12 months in € (insurer perspective)
|
1666.76 (±1821.34)
|
1737.11 (±1091.65)
|
|
Total costs previous 12 months in € (societal perspective)
|
10,679.85 (±17,270.82)
|
7634.41 (±11,252.44)
|
